Monopar Therapeutics
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 10
- Market Cap
- $8.4M
- Introduction
Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.
Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor Cancer
- Conditions
- CancerSolid TumorSolid Tumor CancerOncologyuPAR-positive Solid TumorUrokinase Plasminogen Activator Receptor-positive Solid Tumor
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Monopar Therapeutics
- Registration Number
- NCT06980519
- Locations
- 🇺🇸
Excel Diagnostics & Nuclear Oncology Center, Houston, Texas, United States
MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer
- Conditions
- CancerSolid TumorSolid Tumor, Adult
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Monopar Therapeutics
- Registration Number
- NCT06980506
- Locations
- 🇺🇸
Excel Diagnostics & Nuclear Oncology Center, Houston, Texas, United States
Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors
- Conditions
- Solid Tumor, AdultBladder CancerUrothelial CarcinomaTriple-negative Breast CancerLung CancerColorectal CancerGastric CancerOvarian CancerPancreatic Cancer
- Interventions
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Monopar Therapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT06617169
- Locations
- 🇦🇺
Melbourne Theranostic Innovation Centre (MTIC), North Melbourne, Victoria, Australia
Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
- Conditions
- Ovarian CancerPancreatic CancerSolid Tumor, AdultBladder CancerUrothelial CarcinomaTriple-negative Breast CancerLung CancerColorectal CancerGastric Cancer
- Interventions
- Diagnostic Test: PET/CT Diagnostic Imaging
- First Posted Date
- 2024-03-29
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Monopar Therapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT06337084
- Locations
- 🇦🇺
Melbourne Theranostic Innovation Centre (MTIC), North Melbourne, Victoria, Australia
Camsirubicin + Pegfilgrastim to Determine MTD in ASTS
- First Posted Date
- 2021-09-14
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Monopar Therapeutics
- Target Recruit Count
- 14
- Registration Number
- NCT05043649
- Locations
- 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
🇺🇸University of Washington Medicine Fred Hutchinson Cancer Center, Seattle, Washington, United States
- Prev
- 1
- 2
- Next
News
Monopar Therapeutics Launches FDA-Authorized Expanded Access Program for uPAR-Targeted Radiopharmaceuticals in Advanced Cancers
Monopar Therapeutics and EDNOC have received FDA authorization for an expanded access program providing MNPR-101-Zr imaging agent and MNPR-101-Lu therapeutic agent to patients with advanced solid tumors.
ALXN1840 Shows Promising Long-Term Efficacy and Safety for Wilson Disease at EASL 2025
• Monopar Therapeutics presented late-breaker data at EASL 2025 showing sustained clinical improvements in Wilson disease patients treated with ALXN1840 (tiomolybdate choline) over a median treatment duration of 2.63 years. • The pooled analysis from multiple clinical trials (n=255) demonstrated improvements in patient-reported symptoms, copper mobilization, and clinical assessments, with fewer than 5% of patients experiencing drug-related serious adverse events. • Patients reported higher convenience and effectiveness with ALXN1840 compared to standard of care, suggesting the drug candidate could provide meaningful benefits for the management of this rare genetic condition.
Monopar Therapeutics Advances Wilson Disease and Radiopharmaceutical Programs
Monopar Therapeutics in-licensed ALXN-1840 from Alexion for Wilson disease, planning regulatory discussions with the FDA focusing on patients with severe symptoms.
Monopar Acquires Late-Stage Wilson Disease Drug Candidate ALXN-1840 from Alexion, AstraZeneca Rare Disease
Monopar Therapeutics has acquired ALXN-1840, a late-stage drug candidate for Wilson disease, from Alexion, AstraZeneca Rare Disease, taking over global development and commercialization.